Background: Add-on therapy with aldosterone receptor antagonists has been reported to lower blood pressure (BP) in patients with uncontrolled hypertension. We assessed potential predictors of this response.
INTRODUCTION

D
espite the availability of a large arsenal of antihypertensive agents, blood pressure (BP) remains uncontrolled in a substantial proportion of treated patients [1] . Evidence indicates that these patients are at high risk to develop cardiovascular complications [2] . In patients in whom BP is difficult to control with standard antihypertensive treatment, add-on treatment with an aldosterone receptor antagonist (ARA) has been shown to result in a further BP reduction [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . In retrospective studies, this effect ranged up to 25 mmHg in SBP and 12 mmHg in DBP [7] [8] [9] 11, 14, 15] . Few prospective studies with add-on ARA therapy have been performed and although a BP-lowering effect was always present, BP reductions were considerably smaller [6, 10, 16] . For instance, the first randomized, placebo-controlled trial on the effect of add-on treatment with spironolactone in patients with resistant hypertension showed a reduction of 5.4 mmHg in daytime SBP and 1.0 mmHg in daytime DBP after 8 weeks of spironolactone [16] . The lack of a control group is likely the most important cause of the difference in BP-lowering effect between the retrospective and prospective studies. Other contributing factors may be selection bias and the inclusion of patients with subtle forms of primary aldosteronism in retrospective studies.
As is common for antihypertensive regimens in general, the BP response to add-on ARA shows a wide interindividual variation. Several investigators have tried to identify factors that predict a favorable BP response, but data on predictors have been conflicting. Lower serum potassium levels have been reported by several groups to be associated with a better BP response [7, 8, 10, 17] , possibly pointing out inclusion of patients with undetected primary aldosteronism. Although some publications have demonstrated that a low plasma renin level [16, 18] or a higher aldosterone-to-renin ratio (ARR) [16] is associated with a better response, most investigators have found that the fall in BP is unrelated to plasma renin and aldosterone levels or the ARR [4, 13, [19] [20] [21] . This absent association might be explained by the variable effects of multidrug antihypertensive regimens on aldosterone and renin levels [17] . Other factors reported to be associated with a favorable response were a high baseline BP [11, 12, 22] , a high BMI [22] , an elevated waist circumference, a low aortic pulse wave velocity [10] and a low high-density lipoprotein cholesterol [8] .
The long-term use of spironolactone is limited by the risk of its antiandrogenic and progestogenic side-effects [23] . In this respect, prescription of the more selective ARA eplerenone may have advantages. The potential beneficial effects of eplerenone in patients with resistant hypertension have not been studied extensively. Only Calhoun and White [12] performed an open-label, uncontrolled trial in patients with resistant hypertension showing a significant decrease of 12.2 mmHg in 24-h SBP and of 6 mmHg in 24-h DBP after 12 weeks of eplerenone at a dose of 50-100 mg.
The aim of the present study was to investigate the efficacy of add-on therapy with a fixed dose of the selective ARA eplerenone in patients with persistent hypertension despite the use of at least two antihypertensive agents and to explore the presence of potential determinants for this response. In all patients, primary aldosteronism was excluded by means of an intravenous salt loading test. In addition, the transtubular potassium gradient (TTKG) was assessed as a measure of kidney mineralocorticoid receptor activity [24, 25] .
METHODS
Patients
Male and female patients aged 18-65 years with an office SBP above 140 mmHg and/or an office DBP above 90 mmHg despite the use of at least two antihypertensive drugs were invited to participate. The antihypertensive medication was not necessarily given in the maximal dose. Patients were excluded if a known cause of hypertension was present, in case of cardiac chest pain or heart failure, a cerebrovascular or cardiovascular event within 6 months before inclusion, pregnancy, or a known allergy to eplerenone. Beta-adrenergic blockers as well as potassium-sparing diuretics were discontinued to allow a proper evaluation for the presence of primary aldosteronism. All patients were screened for the presence of primary aldosteronism by the ARR and an intravenous salt loading test [26] . Only patients with a negative salt loading test (as defined by a posttest plasma aldosterone below 235 pmol/l) were included. A total of 28 patients of 183 patients who were initially screened had a positive salt loading test.
Design
At baseline, office BP, a 24-h ambulatory BP measurement (ABPM) and routine biochemical tests were taken. In addition, clinical data, height and weight, and number and types of antihypertensive drugs were recorded. Patients were screened for the presence of left ventricular hypertrophy (LVH) using a standard 12-lead electrocardiogram (EKG) based on the Sokolow-Lyon criteria [27] . At this point, eplerenone 50 mg once daily was started. The other antihypertensive drugs were left unchanged. One week after initiation of eplerenone, office BP was measured, as well as routine biochemical parameters. If serum potassium level exceeded 5.6 mmol/l, eplerenone dose was reduced to 25 mg. In other cases, eplerenone was continued at the initial dose. After 3 months of treatment, office BP, 24-h ABPM and biochemical measurements were repeated. At this point, all hypertensive medications but eplerenone were continued. After another 6 weeks, office BP, 24-h ABPM and biochemical measurements were again performed.
The study was approved by the Institutional Review Board and Ethical Committee of the Erasmus MC in Rotterdam and has been registered at www.clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT00407784). All patients gave written informed consent to participate.
Blood pressure measurements
Office BP levels were recorded as three subsequent measurements after at least 5 min in sitting position with a validated automatic BP measurement device. The mean value of the last two readings was used for the analysis.
Twenty-four-hour ABPM was performed using a locally available validated ABPM monitor. For by far the majority of patients, the Spacelabs 90217 or 90207 ABPM monitor was used (Spacelabs Medical, Issaquah, Washington, USA). In one center, the Mobil-o-Graph ABPM monitor (APC Cardiovascular Ltd., Cheshire, UK) was used. BP was recorded every 20 min during daytime and every 30 min during nighttime. The measurement was considered valid in the case of at least 40 successful readings.
Biochemical measurements
At all visits, serum sodium, potassium, urea, creatinine, bicarbonate, uric acid levels and osmolality were measured using locally available routine laboratory techniques. In addition, urine samples were collected for determination of sodium, potassium, creatinine and osmolality. The TTKG was calculated as [24] . Only urine samples with a urinary Na þ concentration exceeding 25 mmol/l and an osmolality equal or greater than plasma osmolality were used to calculate the TTKG. In some patients, a 24-h urine sample and in other patients a spot urine sample was available. In patients for whom both were available at baseline, the 24-h sample was used to calculate the TTKG. For serial measurements, only urine samples collected via the same sampling method were used.
In the preceding diagnostic phase and after 3 months of treatment, plasma aldosterone concentration (PAC) and plasma renin concentration (PRC) were determined by drawing blood samples in EDTA plasma by venapuncture between 0800 and 1000 h after 10 min in a sitting position. The antihypertensive drugs allowed at the time of sampling were as described previously, that is without beta-adrenergic blocker and potassium-sparing diuretics. The samples were centrifuged at room temperature for 10 min at 3000g. The plasma was then collected and stored at À208C until analysis. PAC was measured with a radioimmunoassay (Coat-a-Count; Diagnostics Product Corporation, Los Angeles, California, USA). PRC was assessed using an immunoradiometric assay (Renin III; Cisbio, Gif-sur-Yvette, France).
Statistical analysis
Values are expressed as mean AE SD, or as median and interquartile range (IQR) when not normally distributed. Categorical values are reported as percentages.
Medication use was quantified by adding up the total number of different antihypertensive drugs, as well as by assessing the defined daily dose (DDD) per drug and for total drug use according to the World Health Organization Anatomical Therapeutic Chemical (ATC) index [28] . Antihypertensive agents were grouped in the following categories: diuretics; renin-angiotensin system (RAS) blockers [i.e. angiotensin-converting enzyme inhibitors (ACE-I), angiotensin-receptor blockers (ARB), and renin inhibitors]; calcium channel blockers (CCBs); beta-adrenergic blocker; alpha-adrenergic blockers; and other antihypertensive drugs.
Upon treatment with eplerenone, changes in BP and biochemical parameters were tested with one-way analysis of variance (ANOVA) for repeated measurements. Post-hoc analysis was performed according to Bonferroni correction for multiple testing. Changes in PAC and PRC were tested with the Wilcoxon signed-rank test because of a skewed distribution.
The differences in 24-h BP at baseline and after 3 months of treatment were grouped in tertiles. Intertertile differences in clinical and biochemical parameters were tested with one-way ANOVA with post-hoc testing according to Bonferroni or the Kruskal-Wallis test for parameters with a nonnormal distribution. To test for differences in proportions, the Pearson x 2 test was applied. To identify predictors for the BP response, multivariate regression analysis was performed with the change in 24-h ABPM (DASBP and DADBP) as dependent variable. Serum potassium, PRC, PAC and the ARR at baseline were selected as covariates based on literature findings as described in the previous section. In addition, variables with an association with the dependent value with a P value less than 0.20 on univariate regression analysis as well as age and sex were included in the model. All analyses were performed in SPSS Statistics 20 for MacOS X (IBM, Armonk, New York, USA).
RESULTS
Study population
A total of 141 patients were included in the study protocol. Twelve patients were excluded before completion of the protocol: four patients because of adverse events, two patients because of a myocardial infarction, one patient because of a hypertensive urgency and five patients were lost to follow-up. Another 12 patients had a switch in antihypertensive medication other than eplerenone and were excluded from the analysis. In total, 117 patients with a mean age of 51 AE 9.7 years were included in the analysis. The mean office BP was 150/92 (AE18/11) mmHg. They used a median number of 3 (IQR 2-3) antihypertensive drugs [total DDD 4.5 (3-5.5)]. Diuretics were used by 75% of patients, RAS blockers by 87%, CCB by 81%, alpha-adrenergic blocker by 22% and other antihypertensive drugs by 1.7% of patients. Note that beta-adrenergic blockers were discontinued in an earlier phase to allow a proper diagnostic workup for primary aldosteronism. However, one patient still used a beta-adrenergic blocker at inclusion. Eleven percent had diabetes mellitus, 28% smoked (included are patients who quit smoking less than 5 years ago) and 11% had a history of cardiovascular disease. Patient characteristics are displayed in Table 1 .
Blood pressure response Figure 1 shows the mean office BP at baseline, after 1 week of treatment with eplerenone 50 mg, after 3 months of treatment and 6 weeks after discontinuation of treatment. Of the total study population of 117 patients, data of 102 patients were available for this analysis: seven patients were excluded from this analysis because they continued eplerenone after 3 months, and of eight patients, BP values of one of the visits were missing. In four patients, the eplerenone dose was reduced to 25 mg (because of palpitations in one patient and for unknown reasons in three patients). SBP dropped from 149.0 AE 17.8 to 144.1 AE 16.7 mmHg after 1 week, and to 141.8 AE 18.7 mmHg after 3 months. When eplerenone was stopped, SBP returned to baseline values (149.9 AE 19.7 mmHg, P < 0.001 for total trend). DBP levels were 90.7 AE 11.0, 88.1 AE 10.9, 86.6 AE 12.8 and 90.9 AE 13.3 mmHg at baseline, after 1 week of treatment, after 3 months of treatment and 6 weeks after discontinuation, respectively (P < 0.001 for total trend). The pulse rate was similar at all time points.
A similar pattern was observed for 24-h ABPM at baseline, after 3 months of eplerenone treatment and 6 weeks after discontinuation (Fig. 2 , total number available for analysis was 97 patients). Ambulatory SBP (ASBP) decreased from 140.7 AE 15.1 to 132.3 AE 15.7 mmHg (P < 0.001), and ambulatory DBP (ADBP) from 87.3 AE 8.3 to 82.6 AE 10.6 mmHg (P < 0.001). After cessation of eplerenone, ASBP rose again to 138.7 AE 16.6 mmHg (P < 0.001) and ADBP to 85.9 AE 9.6 mmHg (P < 0.001).
Biochemical changes
There was a small but significant rise in serum potassium and serum creatinine after start with eplerenone (Table 2) . This rise was consistent during the total treatment period and values returned to baseline after eplerenone was stopped. Serum sodium and bicarbonate showed a marginal lower value with eplerenone. The TTKG was significantly lower after 3 months of treatment compared to baseline (P ¼ 0.028; Table 2 ). Median renin levels increased from 30.2 (IQR 12.5-71.9) mU/l at baseline to 55.0 (18.7-154.1) mU/l (P < 0.001) after 3 months. PAC rose from 241 (158-388) to 396 (242-576) pmol/l (P < 0.001). There was a trend toward a slightly higher ARR after treatment (P ¼ 0.071; Table 2 ).
Determinants for the blood pressure response
To identify potential predictors for the BP response to eplerenone, the differences in ASBP (DASBP) and ADBP (DADBP) between baseline and after 3 months of treatment were arranged in tertiles. Patients with valid ABPM data available at both time points were included in this analysis (n ¼ 103). Table 3 shows the clinical characteristics for each tertile. Patients in the highest tertile for DASBP were older than those in the lowest tertile (53.8 AE 8.1 compared to 48.0 AE 10.3 years, P ¼ 0.039). In addition, a larger proportion of patients with a poor response had LVH. There were no other differences in BP, biochemical profile and medication use between the tertiles. Subsequently, a multivariate linear regression analysis was performed for DASBP and DADBP (Table 4) . A higher baseline ASBP was associated with a greater reduction in ASBP. The presence of LVH was associated with a smaller response. For DADBP, no significant predictors were found, although a trend existed toward a smaller response for patients with LVH. Of note, neither serum potassium levels nor the ARR predicted the BP response. Substitution of the ARR by PRC and PAC showed no significant relation (data not shown). In addition, the 24-h sodium excretion, the change in PRC after eplerenone treatment and the number and subclasses of antihypertensive medication had no association with the BP response at univariate regression analysis and were not included in the multivariate model (data not shown).
Adverse events
Of the initial study population of 141 patients, 44 patients reported a total of 57 adverse events. Most adverse events were mild and had no suspected relation to treatment. Most reported were dizziness (14%), gastrointestinal complaints (12.3%), tiredness (10.5%), headache (7%) and edema and weight gain (7%). Seven patients left the study protocol because of adverse events: two patients had a myocardial infarction during eplerenone treatment, one patient had a hypertensive urgency, three patients had gastrointestinal 
DISCUSSION
Several studies have demonstrated that treatment of patients with resistant hypertension with ARAs leads to a further, in many cases impressive, BP reduction. However, most of these studies have methodological limitations, being retrospective, lacking objective BP recordings or a placebo-controlled design and including patients with primary aldosteronism [3] [4] [5] [7] [8] [9] 11, 12, 14, 15] . In recent years, a few prospective studies have been reported. In these studies, a reduction in BP during add-on therapy with an ARA was still observed, though substantially smaller than that in the retrospective studies [6, 10, 16] . To our knowledge, only one trial has assessed the effect of the selective ARA eplerenone [12] . Our study shows that the addition of eplerenone to existing BP-lowering treatment in patients with uncontrolled hypertension, in whom primary aldosteronism was excluded by a salt loading test, results in a significant decrease in both office and 24-h ambulatory BP. After 3 months of treatment, ambulatory BP was reduced by 8.4 mmHg systolic and 4.7 mmHg diastolic. This response is of comparable magnitude as reported in other studies in which 24-h ABPM or a placebo-controlled design was used (Table 5 ).
The mechanism of the BP-lowering effect of ARAs in resistant hypertension is incompletely understood. It has been suggested that a relative aldosterone excess contributes to therapy resistance. In patients with an elevated ARR and plasma aldosterone level, but a negative confirmation test for primary aldosteronism, BP control was more difficult to achieve than in patients with a low ARR [29] . In addition, a large proportion of patients treated with an ACE-I or ARB show 'aldosterone escape', a situation in which aldosterone levels after an initial decline rise to or even above pretreatment levels during prolonged treatment with these agents [30, 31] . This secondary rise in aldosterone counteracts the BP reduction and possibly contributes to therapy resistance. Moreover, aldosterone excess is thought to be an important mediator of structural cardiovascular damage such as arterial stiffness [32, 33] , which in the long run may further increase BP levels and impair the response to BP-lowering agents. From this perspective, it is reasonable to assume that ARAs are particularly effective in patients with aldosterone excess. However, indices of aldosterone excess such as a low renin level, a high ARR or a low serum potassium level have not uniformly been shown to predict the response to ARAs [4, 13, 16, [18] [19] [20] [21] . Likewise, in our study, no relation with any of these variables could be found, although it cannot be ruled out completely that the use of antihypertensive medication at Eplerenone in uncontrolled hypertension the time of sampling with its associated effects on PRC and PAC may have contributed to this lack of correlation. The TTKG, considered to be a measure of aldosterone activity in the distal convoluted tubule and cortical collecting duct [24, 25] , did not correlate with the eplerenone-induced BP reduction, although a small but significant decrease in the TTKG after treatment with eplerenone was observed. Also the 24-h sodium excretion was not related to the reduction in BP. Inhibition of the extrarenal effects of aldosterone such as a direct regulatory action of vascular tone [34] could play a role as well. Only a higher baseline ambulatory SBP was associated with a larger fall in SBP. However, this is a nonspecific response as it has been observed with different classes of antihypertensive drugs. With all limitations in sensitivity [35] , the presence of LVH on the EKG was associated with a smaller response in BP. The presence of LVH usually implies more severe hypertension and structural vascular changes, which in turn may impair the efficacy of BP-lowering agents. Antihypertensive drug use had no effect on BP reduction. It should be noted that beta-adrenergic blockers were discontinued before start of the study protocol. Because beta-adrenergic blockers lead to a reduction in PRC, it could be that these agents can hamper the secondary rise in PRC after eplerenone treatment, thereby potentiating its BP-lowering effect. However, we did not observe a relation between the change in PRC and the BP response, making this influence unlikely.
ARAs are generally well tolerated. However, gynecomastia, erectile dysfunction and menstrual disorders are well known side-effects of spironolactone, especially when used in higher dosages [23] . Eplerenone, being a more selective ARA, has a much lower incidence of sex hormone-related side-effects and can replace spironolactone when this latter compound is not well tolerated [36] . In our study, one patient reported loss of libido, but no cases of gynecomastia or other sex hormone-related side-effects were seen. Although 31% of patients reported an adverse event during treatment with eplerenone, these were predominantly mild and in most cases probably unrelated to the study medication. Because our study lacked a placebo arm, the true incidence of adverse effects attributable to eplerenone cannot be assessed. Two patients developed a myocardial infarction and one patient was excluded because of a hypertensive urgency. A relation with the study medication is unlikely and these events probably reflect the high cardiovascular risk profile of the study population.
Another point of concern during treatment with an ARA is the risk of hyperkalemia and deterioration of renal function. Although a significant rise in serum potassium and creatinine levels after eplerenone treatment was observed, this rise was marginal and remained stable over the treatment period of 3 months. Only one patient had a serum potassium level of 5.9 mmol/l after 1 week of treatment, but this normalized without any dose reduction. Preexistent impairment of renal function [22] , pretreatment elevated potassium levels [22, 37] , higher age, diabetes mellitus and use of beta-adrenergic blocker [37] have all been identified as risk factors for the occurrence of hyperkalemia, whereas a higher baseline serum creatinine and concomitant use of other diuretics were shown to be associated with the development of renal insufficiency [37] . Therefore, the advice remains to closely monitor serum potassium and creatinine levels, especially when such risk factors are present. We also observed a rise in PAC during add-on treatment with eplerenone. This rise is probably related to a rise in PRC due to volume depletion and the rise in potassium concentration.
As mentioned, most studies concerning the BP-lowering effect of add-on ARA therapy are retrospective. Our study further augments the necessary prospective evidence for their efficacy. The most important limitations of our study are the relatively small numbers and the absence of a blinded, placebo-controlled design. However, the use of 24-h ABPM is known to largely preclude the occurrence of observer bias and placebo-related effects [38, 39] . In addition, the almost complete return of BP to baseline levels after cessation of eplerenone provides strong evidence for a genuine treatment effect. Another limitation is that only patients who completed the full trial with no change in medication other than the study medication were included in the analysis. This could have resulted in selection of patients with a favorable response. However, when including all patients with available data at baseline and 3 months of treatment, the The precise delineation of the place of ARAs in the treatment of patients with difficult-to-treat and resistant hypertension has not been well established. Although both in the European and American hypertension management guidelines, the use of an ARA has been recommended in case of resistant hypertension [40, 41] , their place within the therapeutic arena remains to the judgment of the individual physician. This may lead to underuse, as has recently been shown in a retrospective cohort study evaluating the prescription of BP-lowering agents in patients with resistant hypertension. In this large study, ARAs were prescribed in only 5.9% of patients [42] . Reports on how the efficacy of ARAs relates to other forms of add-on treatment are scarce. When studied in a cross-over design, spironolactone had a greater antihypertensive effect than combination treatment with an ACE-I and ARB [13] . Also in comparison to doxazosin, BP reduction was larger when spironolactone was added to the therapeutic regimen in patients with resistant hypertension [9] . As also observed in our study, not all patients with resistant hypertension respond favorably to add-on ARA treatment. Patients with hypertension refractory to BP-lowering treatment in general displayed a smaller response to spironolactone than patients who were responsive to treatment [43] . Segura et al. [44] showed that in these patients, the addition of a triple therapy consisting of substitution of the diuretic with chlorthalidone, addition of amlodipine (if not yet prescribed), and the direct renin inhibitor aliskiren on top of the already used treatment can result in a further relevant BP reduction. Future research should focus on identifying the different mechanisms involved in treatment resistance in order to select the best combination of antihypertensive drugs for each individual patient. Also, comparison of ARAs with innovative treatment modalities such as endovascular catheter-based renal sympathetic denervation [45] would be of great interest. Although renal sympathetic denervation has been reported to have a large effect on office BP, the effect on ambulatory BP is comparable to that observed with add-on ARA treatment [45] . Finally, the importance of lifestyle measures, especially a reduction in dietary salt intake, should be emphasized. The median sodium excretion in our population was 174 mmol per day. Probably, the BP of a large proportion of our patients would have benefited from dietary sodium reduction [46] .
In conclusion, eplerenone effectively lowers BP in patients with difficult-to-treat hypertension without evidence of primary aldosteronism. This effect is unrelated to parameters of aldosterone excess such as a high plasma aldosterone, low plasma renin, high ARR or a high TTKG. In our population, the presence of LVH was associated with a smaller BP reduction. Additional studies to compare aldosterone receptor blockade with other treatment modalities are warranted to select the most optimal treatment strategy for the individual patient with difficult-to-treat or resistant hypertension. Eplerenone in uncontrolled hypertension
